ABPRO HLDGS INC SEC Filings

Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.

Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.

Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.

The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.

On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.

Abpro Holdings, Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, its lead multispecific antibody oncology program. The therapy is being co-developed with Celltrion, Inc., and this clearance allows clinical studies of the candidate to begin under the IND. The update was shared via a press release furnished under a Regulation FD disclosure.

Abpro Holdings, Inc. disclosed that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to initiate a phase 1 clinical trial of its T cell engager candidate ABP-102/CT-P72 for HER2-positive cancers. This marks a step toward first-in-human testing of the therapy, subject to regulatory review.

The update comes via a current report that references a company press release containing further details and includes the release as an exhibit. The company notes that this information is being furnished rather than filed under securities laws, which limits how it is incorporated into other regulatory documents.

Abpro Holdings, Inc. has filed a prospectus supplement that incorporates its Form 10-Q for the quarter ended September 30, 2025. The company reported a net loss of $1.7 million for the quarter and $8.5 million for the nine months, driven mainly by research and development and general and administrative expenses. Cash was only $328 thousand as of September 30, 2025, compared with current liabilities of $17.3 million, resulting in a stockholders’ deficit of $15.6 million. Management concluded there is substantial doubt about Abpro’s ability to continue as a going concern and plans to seek additional equity or debt financing and collaborations. The company implemented a 1-for-30 reverse stock split effective October 31, 2025 and remains under a Nasdaq panel exception through March 30, 2026 after prior noncompliance with minimum bid price, market value of publicly held shares and market value of listed securities requirements.

Abpro Holdings, Inc. filed a Form S-1 for the offer and resale of up to 9,775,017 registered shares of Common Stock issuable under its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. YA may resell these shares from time to time.

The company will not receive proceeds from YA’s resales. Abpro may receive up to $50,000,000 in aggregate gross proceeds from sales of Common Stock to YA under the SEPA, at Abpro’s discretion and subject to SEPA terms.

The filing notes potential market impact from these sales. As context, the shares registered represent approximately 361% of Common Stock outstanding as of November 6, 2025, when 2,705,061 shares were outstanding. The offering table indicates 12,480,078 shares outstanding after the offering. Abpro effected a 1-for-30 reverse stock split on October 31, 2025. The Common Stock and Public Warrants trade on Nasdaq as “ABP” and “ABPWW”.

Abpro Holdings (ABP) filed an 8-K/A amending Item 7.01 to replace the press release furnished as Exhibit 99.1 dated November 4, 2025. The company states no other changes were made to the original report.

The information under Item 7.01 and Exhibit 99.1 is furnished, not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.

Abpro Holdings (ABP) reported that it and Celltrion will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The meeting runs November 6–10, 2025 at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

The disclosure was furnished under Item 7.01 (Regulation FD), and a related press release was provided as Exhibit 99.1. This update focuses on scientific progress and does not include financial results or transaction details.

Abpro Holdings, Inc. announced a one-for-thirty reverse stock split that became effective at 5:01 p.m. on October 31, 2025. The company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Market on November 3, 2025.

The disclosure was made under Regulation FD via an 8-K, with a press release furnished as Exhibit 99.1.